What is HC Wainwright’s Forecast for CRBU Q1 Earnings?

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Caribou Biosciences in a research note issued on Wednesday, March 19th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.43) per share for the quarter. HC Wainwright has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.64) per share. HC Wainwright also issued estimates for Caribou Biosciences’ Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS and FY2025 earnings at ($1.94) EPS.

Other analysts also recently issued research reports about the company. Citigroup decreased their price target on Caribou Biosciences from $30.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, November 26th. Bank of America dropped their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Caribou Biosciences has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Stock Up 4.0 %

Shares of Caribou Biosciences stock opened at $1.04 on Friday. The firm has a market capitalization of $96.73 million, a PE ratio of -0.63 and a beta of 2.34. Caribou Biosciences has a 12-month low of $0.95 and a 12-month high of $5.62. The stock’s fifty day moving average is $1.29 and its 200-day moving average is $1.74.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.08 million during the quarter, compared to analyst estimates of $2.11 million.

Institutional Trading of Caribou Biosciences

Several hedge funds have recently added to or reduced their stakes in CRBU. Intech Investment Management LLC acquired a new stake in Caribou Biosciences during the 3rd quarter worth $43,000. Charles Schwab Investment Management Inc. raised its stake in shares of Caribou Biosciences by 19.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 739,530 shares of the company’s stock valued at $1,449,000 after purchasing an additional 118,325 shares during the period. FMR LLC raised its stake in shares of Caribou Biosciences by 7.4% in the 3rd quarter. FMR LLC now owns 1,581,493 shares of the company’s stock valued at $3,100,000 after purchasing an additional 109,606 shares during the period. Walleye Capital LLC raised its stake in shares of Caribou Biosciences by 45.9% in the 3rd quarter. Walleye Capital LLC now owns 237,599 shares of the company’s stock valued at $466,000 after purchasing an additional 74,799 shares during the period. Finally, PFM Health Sciences LP raised its stake in shares of Caribou Biosciences by 5.5% in the 3rd quarter. PFM Health Sciences LP now owns 4,306,671 shares of the company’s stock valued at $8,441,000 after purchasing an additional 223,299 shares during the period. Institutional investors and hedge funds own 77.51% of the company’s stock.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.